UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 9, 2006
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 0-19700 |
| 33-0266089 |
(State or other jurisdiction |
| (Commission |
| (IRS Employer |
of incorporation) |
| File Number) |
| Identification No.) |
|
|
|
|
|
9360 Towne Centre Drive |
| 92121 | ||
(Address of principal executive offices) |
| (Zip Code) | ||
Registrant’s telephone number, including area code: (858) 552-2200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
The information in this Current Report is being furnished and shall be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934. The information contained in this Current Report and the exhibits attached hereto shall be incorporated by reference into any registration statement or other document filed with the Commission.
On February 9, 2006, Amylin Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth quarter ended December 31, 2005. A copy of this press release is attached as Exhibit 99.1.
Item 8.01 Other Events.
On February 9, 2006, Amylin issued a press release announcing positive results from a 16-week Phase 2 dose-ranging study evaluating the safety and weight effects of pramlintide in obese subjects. A copy of this press release is attached as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits
99.1 Press release issued by Amylin on February 9, 2006.
99.2 Press release issued by Amylin on February 9, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMYLIN PHARMACEUTICALS, INC. | |
|
| |
Dated: February 9, 2006 | By: | /S/ LLOYD A. ROWLAND |
|
| Lloyd A. Rowland |
|
| Vice President, Legal, General Counsel and |
|
| Secretary |
2
Exhibit Index
Exhibit No. |
|
|
99.1 |
| Press release issued by Amylin on February 9, 2006. |
|
|
|
99.2 |
| Press release issued by Amylin on February 9, 2006. |
3
